DBV Technologies S.A. - American Depositary Shares — Bilan (NASDAQ:DBVT)

Afficher le graphique complet Full chart

Financials

Total de l'actif 272.25 M146.72 M246.52 M182.99 M65.66 M233.72 M Total du passif 66.75 M47.45 M52.06 M42.8 M38.27 M64.95 M Total des capitaux propres 205.49 M99.27 M194.45 M140.19 M27.39 M168.77 M Total du passif et des capitaux propres 272.25 M146.72 M246.52 M182.99 M65.66 M233.72 M Dette totale 648 K————— Dette nette 648 K—————

DBV Technologies S.A. - American Depositary Shares

DBV Technologies SA is a publicly owned French biopharmaceutical firm headquartered in Bagneux, France. DBV Technologies is known for developing "Viaskin" technology for administering allergens or antigens to intact skin while avoiding any transfer to the blood. Viaskin Peanut clinical development has received Fast Track designation from the US Food and Drug Administration.

DBVT

Financials

DBV Technologies S.A. - American Depositary Shares

Nouvelles

Is COMPASS Pathways (CMPS) Outperforming Other Medical Stocks This Year?

DBV Technologies: A Cohort-Driven Model That Could Support Blockbuster VIASKIN Revenue

DBV Technologies (DBVT) Upgraded to Buy: What Does It Mean for the Stock?

Wall Street Analysts Predict a 79.04% Upside in DBV Technologies (DBVT): Here's What You Should Know

DBV Technologies: A Tough Nut To Crack In A Shrinking Market (NASDAQ:DBVT)

Cantor Fitzgerald réitère sa note sur DBV Technologies en raison du potentiel du patch

Cantor Fitzgerald réitère sa note de surpondération sur l’action DBV Technologies

Citizens relève l’objectif de cours de DBV Technologies sur les perspectives du médicament contre les allergies

Citizens réitère sa recommandation sur DBV Technologies et le potentiel de Viaskin Peanut

Citizens reiterates DBV Technologies stock rating on Viaskin Peanut potential

Le titre DBV Technologies bondit après de nouvelles données sur le patch contre l’allergie aux arachides

DBV Technologies stock surges on new peanut patch trial data